Relative efficacy of spironolactone, eplerenone, and cAnRenone in patients with chronic heart failure (RESEARCH): a systematic review and network meta-analysis of randomized controlled trials
This study aims to assess the comparative benefit and risk profile of treatment with mineralocorticoid receptor antagonists (MRAs) with regard to all-cause mortality (primary endpoint), cardiovascular mortality, or heart failure (HF)-related hospitalization (secondary endpoints) and the safety endpo...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
[2020]
|
| In: |
Heart failure reviews
Year: 2020, Volume: 25, Issue: 2, Pages: 161-171 |
| ISSN: | 1573-7322 |
| DOI: | 10.1007/s10741-019-09832-y |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1007/s10741-019-09832-y
|
| Author Notes: | Lutz Frankenstein, Svenja Seide, Tobias Täger, Katrin Jensen, Hanna Fröhlich, Andrew L. Clark, Mirjam Seiz, Hugo A. Katus, Paul Nee, Lorenz Uhlmann, Huseyin Naci, Dan Atar |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1694495183 | ||
| 003 | DE-627 | ||
| 005 | 20220818040632.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200414s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10741-019-09832-y |2 doi | |
| 035 | |a (DE-627)1694495183 | ||
| 035 | |a (DE-599)KXP1694495183 | ||
| 035 | |a (OCoLC)1341314633 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Frankenstein, Lutz |d 1973- |e VerfasserIn |0 (DE-588)124198937 |0 (DE-627)63440766X |0 (DE-576)328373281 |4 aut | |
| 245 | 1 | 0 | |a Relative efficacy of spironolactone, eplerenone, and cAnRenone in patients with chronic heart failure (RESEARCH) |b a systematic review and network meta-analysis of randomized controlled trials |c Lutz Frankenstein, Svenja Seide, Tobias Täger, Katrin Jensen, Hanna Fröhlich, Andrew L. Clark, Mirjam Seiz, Hugo A. Katus, Paul Nee, Lorenz Uhlmann, Huseyin Naci, Dan Atar |
| 264 | 1 | |c [2020] | |
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Published online: 30 July 2019 | ||
| 500 | |a Gesehen am 14.04.2020 | ||
| 520 | |a This study aims to assess the comparative benefit and risk profile of treatment with mineralocorticoid receptor antagonists (MRAs) with regard to all-cause mortality (primary endpoint), cardiovascular mortality, or heart failure (HF)-related hospitalization (secondary endpoints) and the safety endpoints hyperkalemia, acute renal failure, and gynecomastia in patients with chronic HF. We conducted a systematic review and network meta-analysis following PRISMA-P and PRISMA-NMA guidelines. From 16 different sources, 14 randomized controlled trials totaling 12,213 patients testing an active treatment of either spironolactone, eplerenone, or canrenone/potassium-canreonate in adults with symptomatic HF due to systolic dysfunction reporting any of the above endpoints were retained. Efficacy in comparison to placebo/standard medical care with respect to all-cause mortality was confirmed for spironolactone and eplerenone while no conclusion could be drawn for canrenone (HR 0.69 (0.62; 0.77), 0.82 (0.75; 0.91), and 0.50 (0.17; 1.45), respectively). Indirect comparisons hint a potential (non-significant) preference of spironolactone over eplerenone (HR 0.84 (0.68; 1.03)). The overall risk of bias was low to intermediate. Results for secondary endpoints as well as sensitivity analyses essentially mirrored these findings. The beta-blocker adjusted meta-analysis for the primary endpoint showed the same tendency as the unadjusted one (HR 0.39 (0.07; 2.03)). Results need to be interpreted with caution, though, as the resultant mix of patient- and study-level covariates produced unstable statistical modeling. We found no significant and systematic superiority of either MRA regarding efficacy toward all endpoints considered in both direct and indirect comparisons. | ||
| 700 | 1 | |a Seide, Svenja |d 1990- |e VerfasserIn |0 (DE-588)1179391268 |0 (DE-627)1067054855 |0 (DE-576)518208621 |4 aut | |
| 700 | 1 | |a Täger, Tobias |d 1981- |e VerfasserIn |0 (DE-588)1026375959 |0 (DE-627)726658243 |0 (DE-576)370501403 |4 aut | |
| 700 | 1 | |a Jensen, Katrin |d 1969-2020 |e VerfasserIn |0 (DE-588)118168061 |0 (DE-627)694729736 |0 (DE-576)291749240 |4 aut | |
| 700 | 1 | |a Fröhlich, Hanna |d 1985- |e VerfasserIn |0 (DE-588)1014274141 |0 (DE-627)705202550 |0 (DE-576)348549091 |4 aut | |
| 700 | 1 | |a Clark, Andrew L. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Seiz, Mirjam |d 1986- |e VerfasserIn |0 (DE-588)1075263913 |0 (DE-627)833121650 |0 (DE-576)443356645 |4 aut | |
| 700 | 1 | |a Katus, Hugo |d 1951- |e VerfasserIn |0 (DE-588)108916618 |0 (DE-627)577155040 |0 (DE-576)289625076 |4 aut | |
| 700 | 1 | |a Nee, Paul |e VerfasserIn |4 aut | |
| 700 | 1 | |a Uhlmann, Lorenz |d 1986- |e VerfasserIn |0 (DE-588)106747627X |0 (DE-627)818782021 |0 (DE-576)426685660 |4 aut | |
| 700 | 1 | |a Naci, Huseyin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Atar, Dan |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Heart failure reviews |d Dordrecht [u.a.] : Springer Science + Business Media B.V, 1996 |g 25(2020), 2, Seite 161-171 |h Online-Ressource |w (DE-627)320454223 |w (DE-600)2006431-7 |w (DE-576)12146556X |x 1573-7322 |7 nnas |a Relative efficacy of spironolactone, eplerenone, and cAnRenone in patients with chronic heart failure (RESEARCH) a systematic review and network meta-analysis of randomized controlled trials |
| 773 | 1 | 8 | |g volume:25 |g year:2020 |g number:2 |g pages:161-171 |g extent:11 |a Relative efficacy of spironolactone, eplerenone, and cAnRenone in patients with chronic heart failure (RESEARCH) a systematic review and network meta-analysis of randomized controlled trials |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s10741-019-09832-y |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20200414 | ||
| 993 | |a Article | ||
| 994 | |a 2020 | ||
| 998 | |g 106747627X |a Uhlmann, Lorenz |m 106747627X:Uhlmann, Lorenz |p 10 | ||
| 998 | |g 108916618 |a Katus, Hugo |m 108916618:Katus, Hugo |d 910000 |d 910100 |e 910000PK108916618 |e 910100PK108916618 |k 0/910000/ |k 1/910000/910100/ |p 8 | ||
| 998 | |g 1075263913 |a Seiz, Mirjam |m 1075263913:Seiz, Mirjam |d 910000 |d 910200 |e 910000PS1075263913 |e 910200PS1075263913 |k 0/910000/ |k 1/910000/910200/ |p 7 | ||
| 998 | |g 1014274141 |a Fröhlich, Hanna |m 1014274141:Fröhlich, Hanna |d 910000 |d 910100 |e 910000PF1014274141 |e 910100PF1014274141 |k 0/910000/ |k 1/910000/910100/ |p 5 | ||
| 998 | |g 118168061 |a Jensen, Katrin |m 118168061:Jensen, Katrin |d 910000 |d 999701 |e 910000PJ118168061 |e 999701PJ118168061 |k 0/910000/ |k 1/910000/999701/ |p 4 | ||
| 998 | |g 1026375959 |a Täger, Tobias |m 1026375959:Täger, Tobias |d 910000 |d 910100 |e 910000PT1026375959 |e 910100PT1026375959 |k 0/910000/ |k 1/910000/910100/ |p 3 | ||
| 998 | |g 1179391268 |a Seide, Svenja |m 1179391268:Seide, Svenja |d 910000 |d 999701 |e 910000PS1179391268 |e 999701PS1179391268 |k 0/910000/ |k 1/910000/999701/ |p 2 | ||
| 998 | |g 124198937 |a Frankenstein, Lutz |m 124198937:Frankenstein, Lutz |d 910000 |d 910100 |e 910000PF124198937 |e 910100PF124198937 |k 0/910000/ |k 1/910000/910100/ |p 1 |x j | ||
| 999 | |a KXP-PPN1694495183 |e 3623069256 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"name":{"displayForm":["Lutz Frankenstein, Svenja Seide, Tobias Täger, Katrin Jensen, Hanna Fröhlich, Andrew L. Clark, Mirjam Seiz, Hugo A. Katus, Paul Nee, Lorenz Uhlmann, Huseyin Naci, Dan Atar"]},"note":["Published online: 30 July 2019","Gesehen am 14.04.2020"],"person":[{"given":"Lutz","display":"Frankenstein, Lutz","family":"Frankenstein","role":"aut"},{"display":"Seide, Svenja","given":"Svenja","family":"Seide","role":"aut"},{"role":"aut","family":"Täger","display":"Täger, Tobias","given":"Tobias"},{"family":"Jensen","role":"aut","given":"Katrin","display":"Jensen, Katrin"},{"role":"aut","family":"Fröhlich","given":"Hanna","display":"Fröhlich, Hanna"},{"given":"Andrew L.","display":"Clark, Andrew L.","family":"Clark","role":"aut"},{"family":"Seiz","role":"aut","given":"Mirjam","display":"Seiz, Mirjam"},{"family":"Katus","role":"aut","display":"Katus, Hugo","given":"Hugo"},{"display":"Nee, Paul","given":"Paul","family":"Nee","role":"aut"},{"display":"Uhlmann, Lorenz","given":"Lorenz","role":"aut","family":"Uhlmann"},{"display":"Naci, Huseyin","given":"Huseyin","role":"aut","family":"Naci"},{"given":"Dan","display":"Atar, Dan","family":"Atar","role":"aut"}],"recId":"1694495183","physDesc":[{"extent":"11 S."}],"id":{"eki":["1694495183"],"doi":["10.1007/s10741-019-09832-y"]},"title":[{"subtitle":"a systematic review and network meta-analysis of randomized controlled trials","title":"Relative efficacy of spironolactone, eplerenone, and cAnRenone in patients with chronic heart failure (RESEARCH)","title_sort":"Relative efficacy of spironolactone, eplerenone, and cAnRenone in patients with chronic heart failure (RESEARCH)"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"origin":[{"dateIssuedKey":"2020","dateIssuedDisp":"[2020]"}],"relHost":[{"origin":[{"publisher":"Springer Science + Business Media B.V ; Kluwer Acad. Publ.","dateIssuedDisp":"1996-","dateIssuedKey":"1996","publisherPlace":"Dordrecht [u.a.] ; Dordrecht [u.a.]"}],"id":{"zdb":["2006431-7"],"eki":["320454223"],"issn":["1573-7322"]},"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title":"Heart failure reviews","title_sort":"Heart failure reviews"}],"recId":"320454223","disp":"Relative efficacy of spironolactone, eplerenone, and cAnRenone in patients with chronic heart failure (RESEARCH) a systematic review and network meta-analysis of randomized controlled trialsHeart failure reviews","type":{"bibl":"periodical","media":"Online-Ressource"},"pubHistory":["1.1996 -"],"note":["Gesehen am 05.12.05"],"part":{"text":"25(2020), 2, Seite 161-171","pages":"161-171","extent":"11","issue":"2","volume":"25","year":"2020"},"language":["eng"]}]} | ||
| SRT | |a FRANKENSTERELATIVEEF2020 | ||